Welcome to our dedicated page for Anaptysbio SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AnaptysBio, Inc. (ANAB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company focused on immunology therapeutics, AnaptysBio uses these filings to report material events related to its clinical programs, collaborations, capital allocation decisions and strategic plans.
Recent Form 8-K filings describe several categories of information. Some filings report results of operations and financial condition, where AnaptysBio furnishes press releases detailing quarterly financial results and business updates. Others fall under Regulation FD disclosure, such as filings that provide updated corporate investor presentations or slide decks used in conference calls discussing programs like ANB033 or the company’s broader pipeline.
Additional 8-Ks highlight other events, including board authorization of amendments to the company’s stock repurchase plan and the board’s approval of plans to explore separating AnaptysBio’s business into two independent, publicly traded companies by the end of 2026. Filings also cover the company’s Verified Complaint in Delaware Chancery Court against Tesaro and GSK concerning the Collaboration and Exclusive License Agreement for Jemperli, as well as references to Tesaro and GSK’s complaint against AnaptysBio.
For investors analyzing ANAB, these filings help clarify how AnaptysBio reports litigation developments, collaboration terms, royalty monetization arrangements, and major strategic decisions. On Stock Titan, SEC documents are paired with AI-powered summaries that explain the main points of each filing in plain language, highlight notable items such as litigation updates or changes to repurchase plans, and make it easier to scan multiple 8-Ks and other forms without reading every line of legal text.
AnaptysBio’s chief legal officer reported option exercises and share sales. On December 16–18, 2025, the officer exercised employee stock options to buy common stock at $14.02 and $20.16 per share, then sold portions of the resulting shares in several trades.
Sales were made under a pre-arranged Rule 10b5-1 trading plan, with weighted average sale prices including $44.6756, $45.2369 and $46.00 per share. After these transactions, the officer directly owned 8,947 shares of common stock and held fully vested options covering 53,000 shares, plus additional options to purchase up to 414,810 shares that vest according to their terms.
AnaptysBio, Inc. reported an insider stock transaction by its Chief Financial Officer. On 12/16/2025, the CFO exercised an employee stock option to buy 10,000 shares of common stock at an exercise price of $20.16 per share, increasing directly held shares.
That same day, the CFO sold 9,365 shares at a weighted average price of $44.6152 per share and 6,360 shares at a weighted average price of $45.2062 per share under a pre-arranged Rule 10b5-1 trading plan adopted on April 11, 2025. After these transactions, the CFO directly owned 15,761 and then 9,401 shares of common stock and continued to hold 70,600 vested stock options reported in the table, plus additional options to purchase up to an aggregate of 339,440 shares that vest according to their terms.
AnaptysBio, Inc. reported that its Board of Directors authorized an amendment to its Stock Repurchase Plan, allowing the company to repurchase up to an additional $100.0 million of its outstanding common stock. This expands the capital return program beyond the existing authorization.
As of November 20, 2025, $6.4 million remained available under the current $75.0 million Stock Repurchase Plan. The company has already repurchased 3,443,188 shares of common stock, representing 11.2% of shares outstanding before the start of the plan, signaling a significant reduction in its share count over time.
AnaptysBio filed an 8-K noting two communications updates. The company furnished an updated corporate investor presentation as Exhibit 99.1 under Item 7.01 (Regulation FD), which is not deemed “filed” under the Exchange Act. It also filed a press release as Exhibit 99.2 under Item 8.01 announcing top-line Phase 2 data in ulcerative colitis for rosnilimab.
The filing lists Exhibits 99.1 (November 2025 presentation), 99.2 (press release dated November 10, 2025), and 104 (cover page XBRL). No financial results or transactional terms are included in this excerpt.
AnaptysBio (ANAB) reported stronger Q3 results and outlined a potential separation. For the three months ended September 30, 2025, collaboration revenue reached $76.3 million, driven by GSK-related royalties and milestones, while operating expenses were $41.6 million. Income from operations was $34.7 million, and net income was $15.1 million (diluted EPS $0.52).
The company recognized a $50.0 million Jemperli sales milestone in Q3 and recorded royalty revenue of $26.3 million. Non‑cash interest expense tied to royalty monetizations was $22.5 million in Q3. Cash and cash equivalents were $109.8 million, with short‑term investments of $139.1 million. A liability related to the sale of future royalties totaled $331.8 million, and stockholders’ equity stood at a $29.4 million deficit. The company repurchased 3.34 million shares for $65.2 million, leaving $9.8 million authorized.
Strategically, the Board approved exploring a separation into two public companies: one focused on managing GSK/Vanda milestones and royalties, and another advancing immunology programs including rosnilimab, ANB033 and ANB101, with completion targeted by year‑end 2026, subject to approvals.
AnaptysBio (ANAB) furnished an 8-K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025. The release is attached as Exhibit 99.1 dated November 4, 2025.
The Item 2.02 information, including Exhibit 99.1, is furnished and not deemed “filed” and is not incorporated by reference except as expressly stated in future filings. An inline XBRL cover page is included as Exhibit 104.
AnaptysBio, Inc. (ANAB) filed a Form 8-K announcing that on October 14, 2025 it will host a conference call to discuss ANB033 and use a slide presentation during the call. The company also updated its corporate investor presentation on the same date.
Both presentations are furnished under Regulation FD as Exhibits 99.1 and 99.2 and, as stated, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference except as expressly set forth by specific reference.
Eric J. Loumeau, Chief Legal Officer of AnaptysBio, Inc. (ANAB), reported both purchases and sales of company common stock on 09/30/2025. He acquired 5,000 shares by exercising employee stock options at an exercise price of $14.02 and an additional 1,325 shares under the company ESPP included in the reported holdings, bringing his post-transaction direct ownership to 17,328 shares. He also sold 8,240 shares at $29.00 per share under a 10b5-1 trading plan adopted April 11, 2025.
The Form 4 shows he retains outstanding options to purchase 68,000 shares exercisable under the option described and additional unvested options aggregating up to 422,310 shares that vest per their terms. Transactions were routine insider activity documented under Section 16 reporting rules.